Online inquiry

IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (CAT#: GTTS-WQ9467MR)

This product GTTS-WQ9467MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets C5AR1 gene. The antibody can be applied in Solid tumors research.

Specifications
Product type	mRNA
Modified bases	5-Methyl-CTP & Pseudo-UTP
5' Cap	Cap 0
Species	Homo sapiens
RefSeq	NM_001736.4
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	728
UniProt ID	P21730

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9467MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ921MR	IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))	mRNA	ABBV-221
GTTS-WQ14564MR	IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	aCD1919
GTTS-WQ7196MR	IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	FMC63 scFv-8A-F9Z CAR
GTTS-WQ13677MR	IVTScrip™ mRNA-Anti-TNFSF13B, RC18(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	RC18
GTTS-WQ10509MR	IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	LY3002813
GTTS-WQ6414MR	IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))	mRNA	CT-011
GTTS-WQ1097MR	IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 1, Pseudo-UTP, 30 nt-poly(A))	mRNA	ABBV-8E12
GTTS-WQ12456MR	IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	NKTR-214

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST